PRADEEP KAFLE |
In the latest online issue of the Lancet Infectious Disease, our team from Patan Hospital working together with Oxford University published an article based on the findings of a randomised controlled trial of two drugs in typhoid fever.
Typhoid, which is spread by fecal oral transmission is rampant in the developing world, and there is an ongoing problem with drug resistance. This study was the largest clinical trial ( 844 patients were recruited over a period of three years) on typhoid fever to date.
Appropriate dosage of Gatifloxacin was administered for seven days in a once day dosing for patients suspected to have typhoid fever. Gatifloxacin in the study was compared with the oldest drug used in the treatment of typhoid fever, chloramphenicol. There was no difference in the efficacy of these two drugs in the time taken (four days) to bring the fever down. However, unlike cholramhenicol which needs to be taken four times per day for 14 days, gatifloxacin needs to be taken only once a day for seven days. Clearly most people will favour taking a drug once a day for seven days rather than four times a day for 14 days. Our conclusion was that gatifloxacin should be the preferred drug in the treatment of typhoid fever in the developing world.
